UBS raises target for Vertex Pharma stock from USD 585.00 to USD 615.00

Published on 10/06/2026 at 10:47 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Revenue rose 12.50 percent to USD 3.33 billion in the second quarter of 2026. Vertex Pharma stock costs EUR 449.23 on October 6, 2026 versus EUR 449.43.

Aquarellbild der Boston-Skyline mit Segelbooten am Hafen im warmen Licht — Vertex Pharma US92532F1003 zeigt die Boston Skyline am Wasser in weicher Aquarell-Malerei-Optik mit Segelbooten, Illustration mit AI erstellt.

Vertex Pharmaceuticals (ISIN US92532F1003) was trading at EUR 449.23 at Lang & Schwarz on October 6, 2026, with the euro quote down 0.04 percent versus the prior close of EUR 449.43. On September 28, 2026, UBS raised its target for the stock from USD 585.00 to USD 615.00 and maintained a Buy rating, according to Investing.com. The move puts the analyst view against a market quote that remains below the target, while the central question is whether Vertex can broaden its cystic fibrosis base.

UBS points to kidney data

UBS tied its revised target to upcoming Phase III data for inaxaplin, an oral treatment for APOL1-mediated kidney disease. The interim readout is expected in early 2027 and will evaluate patients with APOL1 risk mutations, severe proteinuria and no other comorbidities, Investing.com reported on September 28, 2026.

The clinical evidence already supplied a measurable reason for the attention. Vertex reported a 42.70 percent reduction in urine albumin to creatinine ratio at Week 13 in one AMPLIFIED Phase 2b cohort, compared with a 17.30 percent reduction in the cohort involving patients with type 2 diabetes, according to Business Wire on September 22, 2026. Vertex also completed enrollment in the Phase 2/3 AMPLITUDE trial, with interim data planned for early 2027.

Second-quarter revenue reaches USD 3.33 billion

Vertex reported revenue of USD 3.33 billion in the second quarter of 2026, up 12.50 percent from the same quarter a year earlier. Adjusted earnings per share came to USD 4.73, compared with a consensus estimate of USD 4.74, while revenue exceeded the USD 3.23 billion estimate, MarketBeat reported on September 21, 2026.

The comparison matters because revenue growth remained positive even as the earnings-per-share result fell USD 0.01 short of consensus. For the stock, the kidney pipeline therefore adds a second valuation pillar, but the pivotal evidence remains ahead rather than already reflected in a completed approval.

Stock stays below its yearly high

Vertex is listed on the NASDAQ under ticker VRTX. Its USD 400.74 to USD 560.25 52-week range and USD 127.8 billion market capitalization were shown as of October 5, 2026, placing the Lang & Schwarz quote in a separate euro reference frame.

EUR 449.23 in trading

At 10:39 a.m. CEST on October 6, 2026, Vertex Pharma stock was trading at EUR 449.23 at Lang & Schwarz, down 0.04 percent versus the EUR 449.43 prior close dated October 5, 2026. The reference quote is intraday, while the next major company-specific valuation test is the Phase III kidney-disease data cited by UBS.

The further course of trading is shown by the continuously updated real-time quote of Vertex Pharma stock.